Conestat alfa
Also known as: ATryn-related HAE therapy, C1-inhibitor (recombinant), recombinant human C1 inhibitor, recombinant human C1‑esterase inhibitor, rhC1-INH, rhC1‑INH, Ruconest
Source Conestat alfa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human C1‑esterase inhibitor (conestat alfa, brand Ruconest) used as a single intravenous infusion for the treatment of acute hereditary angioedema attacks in patients with C1‑INH deficiency.
Mechanism of Action
Replaces deficient C1‑esterase inhibitor, inhibiting plasma kallikrein and factor XIIa, thereby reducing bradykinin generation and attenuating complement activation.
Routes of Administration
Goals & Uses
- Acute hereditary angioedema attack treatmentTherapeuticHigh
- Treatment of acute HAE attacksTherapeuticHigh
- Reduction of bradykinin-mediated edemaTherapeuticHigh
- Complement pathway regulationMechanisticHigh
- Prophylaxis of HAE attacksTherapeuticLow
Contraindications
- Rabbit allergyHypersensitivityHigh
- Hypersensitivity to conestat alfa or any excipientsAllergyHigh
- Hypersensitivity to conestat alfa or excipientsHypersensitivityHigh
Adverse Effects
- Thrombotic eventsCardiovascularRare
- Infusion‑related reactions (e.g., erythema, flushing)GeneralUncommon
- Hypersensitivity / anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- Injection/infusion site reactionsLocalUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- ACE inhibitorsModerate
- tPA (tissue plasminogen activator)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Children <1 year of ageAgeAbsolute
- BreastfeedingReproductiveRelative
- Pediatric patients under 13 yearsAgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionApprovedApproved: Acute treatment of hereditary angioedema attacks in patients with C1‑INH deficiencyEMA‑approved; same indication as US.
- United StatesApprovedApproved: Acute treatment of hereditary angioedema attacks in patients with C1‑INH deficiencyFDA‑approved; prescription‑only.
- United KingdomApprovedApproved: Treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults and adolescents (≥13 years)Retains approval in UK post-Brexit under MHRA; same indications as EU approval.
FDA‑approved (2017) for acute HAE attacks; also approved by EMA. Administered IV; dosage based on body weight (20 U/kg).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Conestat alfa?
Recombinant human C1‑esterase inhibitor (conestat alfa, brand Ruconest) used as a single intravenous infusion for the treatment of acute hereditary angioedema attacks in patients with C1‑INH deficiency.
What is Conestat alfa used for?
Conestat alfa is educationally associated with: Acute hereditary angioedema attack treatment, Treatment of acute HAE attacks, Reduction of bradykinin-mediated edema, Complement pathway regulation, Prophylaxis of HAE attacks. Educational only — not medical advice.
How is Conestat alfa administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Conestat alfa?
Reported adverse effects include: Thrombotic events, Infusion‑related reactions (e.g., erythema, flushing), Hypersensitivity / anaphylaxis, Headache, Injection/infusion site reactions, Nausea, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Conestat alfa?
Recorded contraindications: Rabbit allergy, Hypersensitivity to conestat alfa or any excipients, Hypersensitivity to conestat alfa or excipients. Consult a qualified clinician before use.